|
Accueil > Actualité
Sensorion: continuation of Audiogene study recommended
(CercleFinance.com) - Sensorion announces that the Data Monitoring Committee (DMC) has recommended the continuation of the Audiogene phase 1/2 clinical trial, designed to evaluate the intra-cochlear injection of SENS-501 to treat hearing loss linked to mutations in the OTOF gene.
The DMC's recommendation confirms the favorable safety profile of SENS-501 at the first dose tested in children aged 6 to 31 months at the time of administration. Intracochlear administration was also well tolerated. The committee recommended that the study proceed as planned with the evaluation of the second dose, the planned continuation of the dose-escalation portion of the trial. Recruitment of the second cohort (three patients) should be completed by the end of the first half of the year. Copyright (c) 2025 CercleFinance.com. All rights reserved. |
17/04/2025 18:18
L'Oréalhausse de 4,4% du chiffre d'affaires trimestriel 17/04/2025 18:12 Accoren négociation exclusive avec Royal Holiday 17/04/2025 18:01 Tarkettléger repli organique des ventes au 1er trimestre 17/04/2025 17:37 RubisUBS Group franchit les 5% du capital 17/04/2025 17:20 Monclerrepli du titre, un broker abaisse sa cible 17/04/2025 17:00 SafranCapital Group Companies sous les 5% des votes Tous les articles sociétés |
